Therefore, higher nuclear β-catenin levels predicted unfavorable outcome and correlated with elevated Ki-67, suggesting that the β-catenin pathway could be a potential target for treating pancreatic cancer. This evidence concerns the gene MKI67 and familial pancreatic carcinoma.